Condition Lookup
Sub-Category:
Other Cancer Predispositions
Number of Conditions: 2
Retinoblastoma (RB1 gene mutation)
Specialty: Genetics
Category: Cancer Genetics
Sub-category: Other Cancer Predispositions
Symptoms:
white pupillary reflex (leukocoria); strabismus (crossed eyes); poor vision; eye redness or swelling; proptosis (bulging eye in advanced stages)
Root Cause:
Mutations in the RB1 tumor suppressor gene lead to uncontrolled cell growth in the retina.
How it's Diagnosed: videos
Comprehensive eye examination, imaging studies (ultrasound, MRI, or CT of the eye), genetic testing to confirm RB1 mutation, and biopsy in rare cases.
Treatment:
Enucleation (surgical removal of the eye) in advanced cases, focal therapies (laser therapy, cryotherapy), chemotherapy (systemic, intra-arterial, or intravitreal), and radiation therapy.
Medications:
Chemotherapeutic agents such as carboplatin (platinum-based chemotherapy), vincristine (microtubule inhibitor), and etoposide (topoisomerase inhibitor) are commonly used to treat retinoblastoma.
Prevalence:
How common the health condition is within a specific population.
Affects approximately 1 in 15,000–20,000 live births globally; most common in children under 5 years old.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Family history of RB1 mutation, parental germline mutations, and advanced paternal age (associated with sporadic cases).
Prognosis:
The expected outcome or course of the condition over time.
Excellent if diagnosed early; survival rates exceed 95% in developed countries. Prognosis decreases if metastatic disease is present.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Spread to the brain and bone marrow, vision loss, and secondary cancers in survivors with germline RB1 mutations.
Von Hippel-Lindau disease (VHL gene mutation)
Specialty: Genetics
Category: Cancer Genetics
Sub-category: Other Cancer Predispositions
Symptoms:
hemangioblastomas (brain, spinal cord, retina); pheochromocytomas (adrenal tumors); renal cell carcinoma; cysts in kidneys, pancreas, or other organs; hearing loss (endolymphatic sac tumors); headaches; hypertension
Root Cause:
Mutations in the VHL tumor suppressor gene impair protein regulation, leading to abnormal cell growth and angiogenesis.
How it's Diagnosed: videos
Clinical evaluation, imaging (MRI, CT), genetic testing to confirm VHL mutation, and family history assessment.
Treatment:
Regular surveillance for tumor detection, surgical removal of tumors (hemangioblastomas, renal cell carcinoma), and targeted therapies (VEGF inhibitors) for advanced cases.
Medications:
Sunitinib and pazopanib , both VEGF inhibitors, are used for managing advanced renal cell carcinoma. Cabozantinib may also be considered.
Prevalence:
How common the health condition is within a specific population.
Occurs in approximately 1 in 36,000–45,000 individuals; inherited in an autosomal dominant pattern.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Family history of VHL, inheriting a single pathogenic VHL gene mutation.
Prognosis:
The expected outcome or course of the condition over time.
Early detection and management can significantly improve outcomes. Regular screening helps prevent life-threatening complications.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Malignant transformation of renal tumors, neurological damage from hemangioblastomas, and hypertensive crises from pheochromocytomas.